Hospital EBITDA margin target of 18-20%
Management reiterated guidance for hospital EBITDA margins to trend towards 18-20% in coming quarters, despite Q1 margin of 15.2%.
FORTIS / guidance tracker
Keep management guidance in view.
Fortis Healthcare · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
margins
ARPOB growth of 4-5% for FY24
Management expects ARPOB to grow 4-5% for the full year, moderating from Q1's 12% growth due to base effects.
Occupancy to trend towards 70% over 2-3 years
Management expects occupancy to reach 70% over the medium term, supported by bed additions and ramp-up.
Addition of ~1,400 beds over 2-3 years
Planned bed additions of 300-400 per year, primarily brownfield expansions in NCR, Mulund, and Kolkata.
Hospital EBITDA margin target of 20%+ for FY25
Management reiterated guidance for hospital business EBITDA margins to exceed 20% for the full year, despite Q1 margin of 18.5% impacted by one-offs and mix.
Agilus rebranding spend of INR 50 crore in FY25
Agilus plans to spend approximately INR 50 crore on rebranding expenses this fiscal year, which will be treated as one-off costs.
Manesar 350-bed facility to be operational in Q2 FY25
The acquired Manesar facility is expected to start operations in the ongoing quarter, initially with 100 beds, ramping up to full capacity over 18 months.
Agilus to return to industry growth by next year
Management expects Agilus to consolidate during FY25 and return to industry-level growth in FY26, driven by brand recovery and network expansion.
Hospital EBITDA margin improvement of ~200 bps for FY26
Management reiterated guidance of 200 bps margin expansion for the hospital business in FY26, supported by case mix improvement and operational efficiencies.
Diagnostics EBITDA margin of 22-23% for FY26
Management expects diagnostics EBITDA margins to remain in the 22-23% range for the full year, with Q2 typically stronger.
Add ~900 beds in FY26, ~50% operationalized this year
Fortis plans to add approximately 900 beds in FY26, including the recently acquired Shrimann Superspecialty Hospital, with about half becoming operational in the current fiscal.
Diagnostics revenue growth to reach low double-digits in 6-8 quarters
Agilus expects revenue growth to trend in the high single-digits over the next few quarters, moving to early double-digits in 6-8 quarters.
20% hospital EBITDA margin by FY25
Management reiterated its target of achieving 20% EBITDA margin for the hospital business in the next financial year, driven by occupancy ramp-up and cost control.
70% occupancy exit rate in FY24
The company expects to exit FY24 with occupancy around 70%, despite seasonal fluctuations and new bed additions.
250 beds to be added in FY24
Brownfield expansions at Mulund, Anandapur, BG Road, and Ludhiana will add approximately 250 beds in the current financial year.
1,800 beds in pipeline over 3-4 years
Total brownfield bed pipeline increased to 1,800 beds, including new projects at Mohali (400 beds) and Shalimar Bagh, plus Manesar (350 beds) over 2.5-3 years.
Hospital EBITDA margin expansion of 200 bps for FY25
Management reaffirmed guidance of 200 bps margin expansion for the hospital business for the full year, factoring in initial losses from Manesar.
Agilus EBITDA margin target of 25-26% by FY27-28
Agilus aims to achieve 25-26% EBITDA margins in 15-18 months, driven by operating leverage and cost optimization.
Brownfield bed additions of 350-400 beds in FY26
Management expects to add 350-400 beds in FY26 through brownfield expansions at Noida, FMRI, Anandapur, and BG Road.
Capex of INR 800-900 crore per year for FY25 and FY26
Annual capex includes maintenance and growth capex for both years, supporting brownfield expansions and equipment upgrades.
Hospital EBITDA margin to exceed initial guidance of 20.5-22.5%
Management indicated possibility of higher margin improvement than guided at the beginning of the year, driven by ramp-up of new units.
Organic bed addition of 400-500 beds in FY26
Company added 550 operational beds in H1 FY26 and expects full-year addition of 400-500 beds.
Diagnostics EBITDA margin of 23-24% for full year FY26
Agilus CFO guided margins to be around 23-24% for the full year, based on H1 performance of 24%.
ARPOB growth of 5-6% in H2 FY26
Management expects ARPOB growth of 5-6% in second half, driven by mix improvement and robotic surgeries.
Hospital EBITDA margin target of 20% by end of FY24
Management expects to achieve 20% EBITDA margin for the hospital business by year-end, driven by occupancy improvement and cost optimization.
Long-term hospital EBITDA margin target of 25% in 3-4 years
Over the next 3-4 years, as brownfield bed expansions ramp up, management aims for 25% EBITDA margin.
~2,200 brownfield beds over next 4 years
Brownfield bed expansion plan to add ~2,200 beds, with ~710 beds expected in FY25, including the Manesar acquisition.
Occupancy expected to trend toward 70% in coming quarters
Management expects occupancy to recover to ~70% in Q4 FY24 and next year, driven by seasonal recovery and international patient rebound.
Hospital margin guidance of 20.5% for FY25
Management expects hospital EBITDA margin to reach 20.5% for the full year FY25, with a medium-term target of 25%.
Diagnostics margin guidance of 21-22% for FY25
Agilus Diagnostics is expected to deliver adjusted EBITDA margin of 21-22% for FY25.
Manesar greenfield to break even by Q1 FY26
The Manesar facility, currently at INR 5 crore monthly revenue, is expected to break even at INR 9 crore per month by Q1 FY26.
Agilus to reach industry growth of 8-10% by Q2 FY26
Agilus expects to return to industry-level growth of 8-10% by Q2 FY26, driven by volume growth.
Brownfield bed addition of 400+ beds in FY27
Targeting over 400 brownfield beds next year, primarily from FMRI expansion (200 beds) and other facilities.
ARPOB growth of 4-5% expected for next two years
Management expects ARPOB to grow 4-5% annually, driven by case mix and price increases.
IHH equity infusion likely in 3-6 months
IHH may infuse fresh equity via preferential allotment to strengthen balance sheet for growth.
FY25 EBITDA margin improvement of ~200bps YoY
Hospital operating EBITDA margin expected to improve by ~200bps in FY25, building on FY24's 18.6% (hospital) and 18.4% consolidated.
Brownfield bed addition of ~700 beds in FY25
Includes 50 beds each at Faridabad and Kalyan, 100 beds at Manesar (Q2), 100 beds at Kolkata (Q1), and beds at BG Road (Q2).
Medium-term ARPOB growth of 4-5%
ARPOB growth expected to moderate to 4-5% in medium term from 10.8% in FY24, driven by 2-2.5% price increases and case mix improvement.
Agilus put option resolution by Q2 FY25
Management expects to finalize the put option (due Oct 2024) by August-September 2024, with options including IPO revival or buyout via debt/equity.
Hospital revenue growth of 14-15% in FY26
Management expects hospital revenue to grow 14-15% in FY26, with ARPOB growth of 5-6% and volume growth making up the balance.
Hospital EBITDA margin expansion of ~200bps in FY26
Management guided for ~200bps margin expansion in the hospital business for FY26, similar to the improvement seen in FY25.
Agilus double-digit revenue growth and 23% EBITDA margin in FY26
Management targets double-digit revenue growth for Agilus in FY26, with EBITDA margin (net) around 23%, moving towards 25% in a couple of years.
~1,000 bed additions in FY26
Management plans to add approximately 1,000 beds in FY26 through brownfield expansions at Noida, Faridabad, Manesar, FMRI, and BG Road.